Nordic Issuing

Ongoing case

Kancera AB

Back to all cases

Kancera AB Subscribe here

3 May - 17 May 2023Optionsinlösen

New class of drugs against cancer and inflammation

Kancera invents and develops drugs against life-threatening diseases that currently lack effective treatments, with the main focus on developing drug candidates that work through the so-called the fractal system. Fractalkine is a natural signaling substance that precisely controls both immune cells and cancer cells. Independent research groups have shown that the fractalkine system is a critical factor in the severity of inflammation and cancer development in humans. Kancera is a world leader in the development of small molecule inhibitors of the fractalkine system

Read more on the company's website

The offer in summary

Subscription period: 3 May - 17 May 2023

Subscription price: SEK 3.00

The offer: 7 794 808 shares

Market Place: Nasdaq First North Growth Market

Financial adviser: Stockholm Corporate Finance


Due to restrictions in applicable law in the United States, Canada, Australia, Hong Kong, Singapore, South Africa, Switzerland, New Zealand, Japan, Russia, Belarus or other countries where participation requires further prospectuses, registrations or actions other than those under Swedish law, the offer to subscribe for securities in this offer is not directed at persons or others with registered address in any of these countries.